Whether giritinib is effective or not has been announced in China

Gilitinib is an oral therapeutic drug targeting FLT3 gene mutations. It is mainly used to treat relapsed or refractory acute myeloid leukemia (AML). By inhibiting the activity of FLT3 protein kinase, giritinib can block abnormal cell signaling pathways, thereby inhibiting the growth and proliferation of leukemia cells.

Giritinibis a highly effectiveTKI that acts on Flt3/Axl with an IC50 value of 0.29nM/<1nM. Flt3 is an oncogenic tyrosine kinase that promotes cancer growth. This oral small molecule inhibitor, whose structure is based on a pyrazine carboxamide scaffold, also inhibits Ltk and Alk kinases as well as targets such as p-Erk1/2, p-S6, p-Flt3, p-Akt and p-Stat5. In vivo, Giritinib shows higher affinity to tumor tissue. GIRITINIB can inhibitFlt3/Axl phosphorylation and downstream signaling, further alleviate symptoms and prolong the overall survival of patients.

The original drug of geritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan. The price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. Generic drugs of giritinib are currently produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to the exchange rate).